Le Lézard
Classified in: Health
Subject: TRI

OliX Pharmaceuticals receives Clinical Trial Authorization in the UK to initiate Phase I study with OLX10010, an anti-scar RNAi therapeutics


SUWON, South Korea, May 29, 2018 /PRNewswire/ -- OliX Pharmaceuticals Inc., a leading developer of RNA interference (RNAi) therapeutics (CEO: Dong-ki Lee, Ph.D.), announced that it received the Phase I clinical trial authorization (CTA) with its anti-scar drug, OLX10010, from Medicines and Healthcare products Regulatory Agency (MHRA) in the UK as of May 11, 2018. "The approval of this CTA marks an important milestone for OliX's RNAi therapeutic development, by demonstrating that OliX has met and qualified against the high standards of a European regulatory agency" noted Dong-ki Lee, CEO of OliX. The detailed information on the trial has been posted in ISRCTN registry which is a global clinical trial registry.

Hypertrophic scar, the main indication of OLX10010, results from the over-growth of dense fibrous tissue that can develop during the wound healing process after a skin injury or surgery, which may cause functional impairment and cosmetic disfigurement. It is reported that approximately one-third of post-operative patients develop a hypertrophic scar within 12 months. Given the unmet medical needs with no FDA- approved drug, OLX10010 could be a promising therapeutic option for these patients.

Phase I study of OLX10010 in Korea was conducted by Hugel Inc., OliX's co-developer and exclusive distributor in Asia, and completed without any serious adverse events. Covance, a global contract research organization and drug development services company, will conduct the Phase I trial in their specialized clinic, which is expected to be finished by the first half of 2019.

OliX Pharmaceuticals, Inc.

OliX is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The company is currently developing novel therapeutic programs for treatment of various diseases with high unmet medical needs, including hypertrophic scar, dry form of age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF).

David Kwangyong Lee
Director of OliX Pharmaceuticals, Inc. 
T: +82-31-779-8408 
M: +82-10-4226-0174

E: [email protected]

SOURCE OliX Pharmaceuticals, Inc.


These press releases may also interest you

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...



News published on and distributed by: